Abstract
A key component of disease prevention is the identification of at-risk individuals. Microbial dysbiosis and microbe-derived metabolites (MDM) can influence the central nervous system, but their role in disease progression and as prognostic indicators is unknown. To identify preclinical factors associated with Alzheimer’s disease (AD), we compared gut microbiome and metabolome profiles of cognitively healthy subjects, subjective cognitive impairment (SCI) participants and mild cognitive impairment (MCI) participants (n=50 per group, matched for age, BMI and sex), targeting metabolites previously associated with cognitive health (TMAO, bile acids, tryptophan, p-cresol and their derivatives). 16S rRNA bacterial microbiome sequencing and targeted LC-MS/MS were employed for faecal microbiome speciation and serum MDM quantification. Microbiome beta diversity differed between healthy controls and SCI participants. Multiple linear regression modelling highlighted five serum metabolites (indoxyl sulfate, choline, 5-hydroxyindole acetic acid, indole-3-propionic acid (IPA) and kynurenic acid) significantly altered in preclinical AD. Neuroprotective metabolites, including choline, 5-hydroxyindole acetic acid and IPA, exhibited lower concentrations in SCI and MCI in comparison to controls, while the cytotoxic metabolite indoxyl sulfate had higher levels. A Random Forest algorithm with multiclass classification confirmed and extended our results, identifying six metabolites (indoxyl sulfate, choline, 5-hydroxyindole acetic acid, IPA, kynurenic acid, kynurenine) as predictors of early cognitive decline, with an area under the curve of 0.74. In summary, a combined statistical and machine learning approach identified MDM as a novel composite risk factor for the early identification of future dementia risk.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocols were approved by the UK National Research Ethics Service (NRES) Committee, (Study ID: 14/EE/0189) for the CANN and by the University of East Anglia Faculty of Medicine and Health Sciences Ethical Review Committee (Reference: 201819 039) and the UK Health Research Authority (IRAS number: 237251) for the COMBAT study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† These authors share senior authorship
Figure 5 is removed and text has been amended to reflect these changes
Data availability
The 16S rRNA gene sequence data have been deposited in the NCBI BioProject database (https://www.ncbi.nlm.nih.gov/bioproject/) under accession number PRJNA1109848. Other data that support the findings of this study are available from the corresponding authors upon reasonable request.
